Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
about
Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyTight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis.Current status and future prospects for biologic treatments of psoriasis.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials.A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.Fatigue in psoriasis: a phenomenon to be explored.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Adalimumab: A Review in Chronic Plaque Psoriasis.Clinical studies in dermatology require a post-treatment observation phase to define the impact of the intervention on the natural history of the complaint.Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).Fatigue - an underestimated symptom in psoriatic arthritisLong-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).The metabolomics of psoriatic disease.Fatigue and psoriasis.Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis.
P2860
Q26827714-1D12D495-84CA-47A1-A7BD-A377719DB466Q33651502-2CBB7216-0BB4-4343-9AEF-8F0342C0DB5EQ34222693-FB32FAC9-B440-4D34-BAA2-E326F747E1CBQ36057909-B00A8FEF-45CD-4D8D-94CC-CF04EE9648D5Q37517101-BBFC5282-B95D-422B-ABCD-D8D32EA94301Q37631750-1759940D-AEE7-4A98-91AA-3CA333E3D14FQ37915509-1CD8E380-AA7A-4A24-9B63-0FC44EE97B39Q38084325-30CE5A24-6373-43B4-98F8-5475883B1350Q38095548-CB8D7007-F021-4FF9-A613-CB18239895A6Q38150903-5687FC65-1782-44FC-A096-48F57002F7D0Q38207759-1552EB6E-3776-44DE-8300-4F93A616FE0BQ38212907-B8816A48-A14B-412C-A125-6977CEA3DE61Q38306698-5EC698BC-FCF2-4241-B511-3D3EF6A0A87CQ38537167-D02EB685-1A02-44BB-A732-84CE65C212C9Q38557350-E9E5A19B-68E0-4E42-BE26-7A14D7CBE8E6Q38594683-913DB762-5448-42CC-A00F-D1FEE0ACEFB0Q38631012-A1B69F3D-E93A-49E2-9F82-EC86337F655CQ38639495-A4C56018-9991-4599-B8E3-CEE308FD52E4Q38792733-319A69D2-A4E4-4FB6-AD29-36EA45B30C3AQ38920322-35F18513-9468-4A63-A938-F60E20FE51C0Q38965214-C8863C85-967F-4C00-AD46-495C8FFF979EQ40686340-6F5146AB-9BF9-4977-ABDF-A18115001D87Q41170483-1C0C4BD5-AD5A-4BF7-9194-49A983B2D0A8Q42640551-5E40A05B-4FAB-4475-B06D-729EAEA0A39CQ46338726-FE92B51D-0519-41D4-ADE5-07208E823530Q48059175-29114819-08F6-4790-A2F9-8F73C9AC1E16Q48063769-18922245-D2FF-4799-B03E-747E8615EC63Q48227772-259EC746-D3D0-4AF7-BE65-ACE4ABA68962Q48238696-57E71D5D-4506-4A0D-9591-260A1CBBE259Q48478885-9E10A025-8F5C-461E-9FCF-99192A63CB66Q51559341-2FA8B7C4-9857-4682-B0BF-36683AB69AB0Q51826173-BF1C7929-B7EE-489A-8F07-2AEFFA1618AEQ53103335-C457A596-90E2-41B7-9B5E-B785E9A0A02FQ53723878-5DDA508E-D267-49E8-B918-3F1B017E4153Q55193949-6D9D33F3-830E-4308-805F-D8A32335225D
P2860
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Adalimumab for moderate to sev ...... owing withdrawal from therapy.
@en
Adalimumab for moderate to sev ...... owing withdrawal from therapy.
@nl
type
label
Adalimumab for moderate to sev ...... owing withdrawal from therapy.
@en
Adalimumab for moderate to sev ...... owing withdrawal from therapy.
@nl
prefLabel
Adalimumab for moderate to sev ...... owing withdrawal from therapy.
@en
Adalimumab for moderate to sev ...... owing withdrawal from therapy.
@nl
P2093
P2860
P1476
Adalimumab for moderate to sev ...... lowing withdrawal from therapy
@en
P2093
J-P Ortonne
R G Langley
P2860
P304
P356
10.1111/J.1365-2133.2010.10139.X
P407
P50
P577
2011-02-01T00:00:00Z